Satralizumab

Satralizumab (pronunciation: /sætrəˈlɪzjuːmæb/) is a humanized monoclonal antibody designed for the treatment of neuromyelitis optica spectrum disorder (NMOSD). It is marketed under the brand name Enspryng by Roche.

Etymology

The name "Satralizumab" is derived from the International Nonproprietary Names (INN) system, which follows a specific pattern for naming monoclonal antibodies. The "-lizumab" suffix indicates that it is a humanized monoclonal antibody.

Medical Uses

Satralizumab is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is a rare, lifelong, and debilitating autoimmune disease of the central nervous system, characterized by inflammatory lesions in the optic nerves and spinal cord.

Mechanism of Action

Satralizumab works by targeting and inhibiting the interleukin-6 (IL-6) receptor. IL-6 is a cytokine known to play a key role in the inflammatory pathway of NMOSD.

Related Terms

• Monoclonal antibody
• Neuromyelitis optica spectrum disorder
• Interleukin-6
• Aquaporin-4
• Roche

See Also

• List of monoclonal antibodies
• List of drugs used for neuromyelitis optica

External links

• Medical encyclopedia article on Satralizumab
• Wikipedia's article - Satralizumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski